Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03683225 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate in Patients With Parkinsonian Type Disorders
A Phase 2 study of Idiopathic Parkinson Disease, sponsored by Chase Therapeutics Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03683225 is a Phase 2 study of Idiopathic Parkinson Disease that is active but no longer recruiting, run by Chase Therapeutics Corporation. The registered enrollment target is 24 participants, below the 72-participant average among 4 other Idiopathic Parkinson Disease trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03683225, a Phase 2 study of Idiopathic Parkinson Disease, is active but no longer recruiting, sponsored by Chase Therapeutics Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders
Conditions Studied
Interventions
- COMBINATION_PRODUCT CTC-413
Study Locations (1)
Michigan
- Quest Research - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03683225
The ClinicalTrials.gov registry entry for NCT03683225 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 4 other Idiopathic Parkinson Disease trials with a reported enrollment target (67% lower). The listed sponsor is Chase Therapeutics Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which CTC-413 is the first listed.
NCT03683225 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03683225 about?
NCT03683225 is a clinical study titled "A Study to Evaluate in Patients With Parkinsonian Type Disorders". A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders
What is the current status of trial NCT03683225?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-04-01. Estimated completion is 2025-12-30.
What conditions does trial NCT03683225 study?
This clinical trial studies the following conditions: Idiopathic Parkinson Disease.
What interventions are being tested in trial NCT03683225?
The interventions under investigation include: CTC-413 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03683225?
This trial is sponsored by Chase Therapeutics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03683225 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
RECRUITING · Phase 2
-
FDOPA PET and Nutritional Support in Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
COMPLETED · NA
-
Voice Treatment for Parkinson's Disease
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.